Testosterone undecanoate - Clarus Therapeutics

Drug Profile

Testosterone undecanoate - Clarus Therapeutics

Alternative Names: CLR-610; Jatenzo; Oral TU - Clarus; OriTex™; Rextoro; TE - Clarus Therapeutics; Testosterone prodrug; TU

Latest Information Update: 28 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Clarus Therapeutics
  • Class Anabolic steroids; Androstenols; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Testosterone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Hypogonadism

Most Recent Events

  • 26 Jun 2017 Clarus Therapeutics re-submits NDA with the US FDA for Hypogonadism
  • 26 Jun 2017 Efficacy data from a phase III trial in Hypogonadism released by Clarus Therapeutics
  • 28 Feb 2017 Testosterone undecanoate is still at Preregistration stage for Hypogonadism in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top